DocuSign Envelope ID: 021889F1-3BFE-4540-A66E-653B9B8492A1

CV Sciences Certificate of Analysis



This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.

SAMPLE ID:	PRODUCT NAME:
Strength:	
Lot Number:	
Expiration Date:	

CANNABINOIDS*	MG/UNIT	METHOD
CBD		
CBDA		
d9-THC		
THCA-A		
d8-THC		
ТНСV		
CBDV		
CBDVA		
CBGA		
CBG		
CBN		
CBC		
CBL		
Total Cannabinoids		
Sample Size		
THC by Mass		

HEAVY METALS*	STATUS (PASS/FAIL)	METHOD
Arsenic		
Cadmium		
Mercury		
Lead		

DocuSign Envelope ID: 021889F1-3BFE-4540-A66E-653B9B8492A1

CV Sciences Certificate of Analysis



-			
	MICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
	Mold/Mildew/Yeast		
	Aerobic Bacteria		
	Coliforms		
	E. Coli		
	Salmonella		
	Pseudomonas		

PESTICIDES**	STATUS (PASS/FAIL)	METHOD
Total Pesticides		
Mycotoxins	Pass	
RESIDUAL SOLVENTS**	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

- 1. The hemp extract is the product of a batch tested by the independent testing laboratory;
- 2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
- 3. The batch does not contain contaminants unsafe for human consumption.⁺


[†]Tested analytes and limits were set by CV Sciences, Inc.

DB Labs Sample ID #:

*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

Anresco Laboratories Sample ID #:

**Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.





plusCBD 15mg 60ct softgel SKU 107 exp 05/25

\sim			
(anna	hin	α	C
Canna		UIU	0

19.44	4.583		33	0.424
Total CBD (mg/unit)		% Total C	BD	Unit weight (g)
Cannnabinoid	LOQ	Mass	Mass	Concentration
	%	%	mg/g	_
CBD	0.0133	4.583	45.83	
CBDA	0.0133	<loq< td=""><td><loq< td=""><td>1</td></loq<></td></loq<>	<loq< td=""><td>1</td></loq<>	1
d9-THC	0.0133	0.037	0.37	
THCA-A	0.0133	<loq< td=""><td><loq< td=""><td></td></loq<></td></loq<>	<loq< td=""><td></td></loq<>	
d8-THC	0.0133	<loq< td=""><td><loq< td=""><td></td></loq<></td></loq<>	<loq< td=""><td></td></loq<>	
THCV	0.0133	<loq< td=""><td><loq< td=""><td>1</td></loq<></td></loq<>	<loq< td=""><td>1</td></loq<>	1
CBDV	0.0133	0.040	0.40	
CBDVA	0.0133	<loq< td=""><td><loq< td=""><td></td></loq<></td></loq<>	<loq< td=""><td></td></loq<>	
CBGA	0.0133	<loq< td=""><td><loq< td=""><td></td></loq<></td></loq<>	<loq< td=""><td></td></loq<>	
CBG	0.0133	<loq< td=""><td><loq< td=""><td></td></loq<></td></loq<>	<loq< td=""><td></td></loq<>	
CBN	0.0133	<loq< td=""><td><loq< td=""><td>1</td></loq<></td></loq<>	<loq< td=""><td>1</td></loq<>	1
CBC	0.0133	0.073	0.73	
CBL	0.0133	<loq< td=""><td><loq< td=""><td></td></loq<></td></loq<>	<loq< td=""><td></td></loq<>	

Microbiology					
Quantitave Analysis	Status	Sample	LOQ	Limit	
	Pass/Fail	CFU/g	CFU/g	CFU/g	
Mold/Mildew/Yeast	PASS	<loq< td=""><td>80</td><td>10,000</td></loq<>	80	10,000	
Enterobacteriaceae	PASS	<loq< td=""><td>80</td><td>1,000</td></loq<>	80	1,000	
Aerobic Bacteria	PASS	<loq< td=""><td>800</td><td>100,000</td></loq<>	800	100,000	
Coliforms	PASS	<loq< td=""><td>80</td><td>1,000</td></loq<>	80	1,000	
Qualititave Analysis		Detected	or Not-de	etected	
E. Coli	PASS	Not-detected			
Salmonella	PASS	PASS Not-detected			
Pseudomonas	PASS Not-detected				

Heavy Metals

Compound	Status	Sample	LOQ	Limit
	Pass/Fail	PPB	PPB	PPB
Arsenic	PASS	<loq< td=""><td>118</td><td>1500</td></loq<>	118	1500
Cadmium	PASS	<loq< td=""><td>118</td><td>500</td></loq<>	118	500
Mercury	PASS	<loq< td=""><td>118</td><td>1000</td></loq<>	118	1000
Lead	PASS	<loq< td=""><td>118</td><td>500</td></loq<>	118	500

Glen Marquez

Director

 The hemp extract is the product of a batch tested by the independent testing laboratory;
The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of a random sample of the batch; and
The batch does not contain containinants unsafe for human consumption.*



Shaly Define

Sherri Defreece Quality Control



•

The reported result is based on a sample weight with the applicable moisture content for that sample. LOQ = Link of Quantitation. NA = Not Analysed. ND = Not Dedected. PGR = Plant Growth Regulator: Unless etherwise stated all quality control samples performed within specifications ostabilished by the Laboratory. This product has been rested by DB Labs. LLC [MNE# 61887736101164527568] using valid testing methodiogles and a quality system as megained by Newad state low. Values reported relate only to the product tested. DL Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levek of any compounds reported herein. "Bisted analytes and limits were set by the customer. This Certificate shall not be reproduced except in full, without the written approval of DE Labs.

4439 Polaris Ave. Las Vegas, NV 89103 (702)729-5180 www.dblabslv.com



June 07, 2023

CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 **Certificate of Analysis**

Order No. 545110

Sample No. 1162212

SAMPLE INFORMATION

FP-23-0075 plusCBD 15mg 60ct softgel SKU 107 exp 05/25
37036121-1
Non-Inhalable Edible (Capsule)
June 02, 2023

ANALYTICAL RESULTS

Analysis	Residual Solvent Screen 🔮 Pass
Instrument	Gas Chromatography Mass Spectrometry (GC/MS)
Method	MF-CHEM-32
Analysis Date	June 02, 2023 to June 07, 2023

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.2/0.5	ND	1	Pass
Acetone	67/200	ND	5000	Pass
Acetonitrile	67/200	ND	410	Pass
Benzene	0.2/0.5	ND	1	Pass
n-Butane	67/200	ND	5000	Pass
Chloroform	0.2/0.5	ND	1	Pass
Ethanol	67/200	ND	5000	Pass
Ethyl acetate	67/200	ND	5000	Pass
Ethyl ether	67/200	ND	5000	Pass
Ethylene oxide	0.2/0.5	ND	1	Pass
n-Heptane	67/200	ND	5000	Pass
n-Hexane	67/200	ND	290	Pass
Isopropyl alcohol	67/200	ND	5000	Pass
Methanol	67/200	ND	3000	Pass
Methylene chloride	0.2/0.5	ND	1	Pass
n-Pentane	67/200	ND	5000	Pass
Propane	67/200	ND	5000	Pass
Toluene	67/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	67/200	ND	2170	Pass
Trichloroethylene	0.2/0.5	ND	1	Pass

Reported by Anresco, Inc.



June 07, 2023

ND = None Detected

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 page **1** of **1** Report ID: T-2



Certificate of Analysis

June 07, 2023

CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 Order No. 545110 Sample No. 1162212

page 1 of 2

Report ID: T-2

SAMPLE INFORMATION

Description	FP-23-0075 plusCBD 15mg 60ct softgel SKU 107 exp 05/25
Lot Number	37036121-1
Category (Type)	Non-Inhalable Edible (Capsule)
Received	June 02, 2023

ANALYTICAL RESULTS

Analysis	Pesticide Screen 🔮 Pass
Instrument	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method	MF-CHEM-13
Analysis Date	June 02, 2023 to June 07, 2023

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.02/0.06	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.02/0.06	ND	0.02	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.08	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.02/0.06	ND	0.02	Pass
DDVP (Dichlorvos)	0.02/0.06	ND	0.02	Pass
Diazinon	0.02/0.06	ND	0.2	Pass
Dimethoate	0.02/0.06	ND	0.02	Pass
Dimethomorph	0.02/0.06	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.02/0.06	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratorieswww.anresco.comSample #: 11622121375 Van Dyke Ave., San Francisco, CA 94124Batch #: 37036121-1



Certificate of Analysis

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.02/0.06	ND	5.0	Pass
Metalaxyl	0.02/0.06	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.02/0.06	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.02/0.06	ND	0.5	Pass
Oxamyl	0.02/0.06	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.04/0.10	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.02/0.06	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.02/0.06	ND	0.02	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.02/0.06	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.02/0.06	ND	0.02	Pass
Tebuconazole	0.02/0.06	<loq (0.043)<="" td=""><td>2.0</td><td>Pass</td></loq>	2.0	Pass
Thiacloprid	0.02/0.06	ND	0.02	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	<loq (0.027)<="" td=""><td>30.0</td><td>Pass</td></loq>	30.0	Pass

Reported by Anresco, Inc.



June 07, 2023

ND = None Detected

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 Sample #: 1162212 Batch #: 37036121-1 page **2** of **2** Report ID: T-2



Certificate of Analysis

June 07, 2023

CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126 Order No. 545110 Sample No. 1162212

ND = None Detected

SAMPLE INFORMATION

Description	FP-23-0075 plusCBD 15mg 60ct softgel SKU 107 exp 05/25
Lot Number	37036121-1
Category (Type)	Non-Inhalable Edible (Capsule)
Received	June 02, 2023

ANALYTICAL RESULTS

Analysis	Mycotoxins Screen 🔮 Pass
Instrument	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method Analysis Date	MF-CHEM-13 June 02, 2023 to June 07, 2023

Analyte	LOD/LOQ (ppb)	Findings (ppb)	Limit (ppb)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/18	ND	20	Pass

Reported by **Anresco, Inc.**



June 07, 2023

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124

DocuSign

Certificate Of Completion		
Envelope Id: 021889F13BFE4540A66E653B9B84	92A1	Status: Completed
Subject: FP-23-0075 15MG 60CT sOFTGEL COA		
Source Envelope:		
Document Pages: 7	Signatures: 1	Envelope Originator:
Certificate Pages: 4	Initials: 0	Vandana Kothari
AutoNav: Enabled		vandana.kothari@cvsciences.com
Envelopeld Stamping: Enabled		IP Address: 64.207.219.71
Time Zone: (UTC-08:00) Pacific Time (US & Cana	da)	
Record Tracking		
Status: Original	Holder: Vandana Kothari	Location: DocuSign
6/8/2023 8:52:05 AM	vandana.kothari@cvsciences.com	
Signer Events	Signature	Timestamp
Signer Events Vandana Kothari	-	Timestamp Sent: 6/8/2023 8:54:55 AM
-	Signature Vandana kothani	•
Vandana Kothari	-	Sent: 6/8/2023 8:54:55 AM
Vandana Kothari vandana.kothari@cvsciences.com	Vandana kothari	Sent: 6/8/2023 8:54:55 AM Viewed: 6/8/2023 8:58:41 AM
Vandana Kothari vandana.kothari@cvsciences.com DIRECTOR OF QUALITY CV Sciences - Part 11 Security Level: Email, Account Authentication	Vandana kothari Signature Adoption: Pre-selected Style	Sent: 6/8/2023 8:54:55 AM Viewed: 6/8/2023 8:58:41 AM
Vandana Kothari vandana.kothari@cvsciences.com DIRECTOR OF QUALITY CV Sciences - Part 11	Vandana kotlian Signature Adoption: Pre-selected Style Signature ID:	Sent: 6/8/2023 8:54:55 AM Viewed: 6/8/2023 8:58:41 AM
Vandana Kothari vandana.kothari@cvsciences.com DIRECTOR OF QUALITY CV Sciences - Part 11 Security Level: Email, Account Authentication	Vandana kothan Signature Adoption: Pre-selected Style Signature ID: 87A410FF-F032-4873-8900-BEED0868E359	Sent: 6/8/2023 8:54:55 AM Viewed: 6/8/2023 8:58:41 AM
Vandana Kothari vandana.kothari@cvsciences.com DIRECTOR OF QUALITY CV Sciences - Part 11 Security Level: Email, Account Authentication	Vandana kotlian Signature Adoption: Pre-selected Style Signature ID:	Sent: 6/8/2023 8:54:55 AM Viewed: 6/8/2023 8:58:41 AM
Vandana Kothari vandana.kothari@cvsciences.com DIRECTOR OF QUALITY CV Sciences - Part 11 Security Level: Email, Account Authentication	Vandana kothan Signature Adoption: Pre-selected Style Signature ID: 87A410FF-F032-4873-8900-BEED0868E359	Sent: 6/8/2023 8:54:55 AM Viewed: 6/8/2023 8:58:41 AM Signed: 6/8/2023 8:59:22 AM
Vandana Kothari vandana.kothari@cvsciences.com DIRECTOR OF QUALITY CV Sciences - Part 11 Security Level: Email, Account Authentication	Vandana kothan Signature Adoption: Pre-selected Style Signature ID: 87A410FF-F032-4873-8900-BEED0868E359 Using IP Address: 107.132.215.12	Sent: 6/8/2023 8:54:55 AM Viewed: 6/8/2023 8:58:41 AM Signed: 6/8/2023 8:59:22 AM
Vandana Kothari vandana.kothari@cvsciences.com DIRECTOR OF QUALITY CV Sciences - Part 11 Security Level: Email, Account Authentication	Vandana kollari Signature Adoption: Pre-selected Style Signature ID: 87A410FF-F032-4873-8900-BEED0868E359 Using IP Address: 107.132.215.12 With Signing Authentication via DocuSign password	Sent: 6/8/2023 8:54:55 AM Viewed: 6/8/2023 8:58:41 AM Signed: 6/8/2023 8:59:22 AM

ID: e1aa8e52-a247-4777-bd8b-6bacc8ae66c7

In Person Signer Events	Signature	Timestamp	
Editor Delivery Events	Status	Timestamp	
Agent Delivery Events	Status	Timestamp	
Intermediary Delivery Events	Status	Timestamp	
Certified Delivery Events	Status	Timestamp	
Carbon Copy Events	Status	Timestamp	
Witness Events	Signature	Timestamp	
Notary Events	Signature	Timestamp	
Envelope Summary Events	Status	Timestamps	
Envelope Sent Certified Delivered Signing Complete Completed	Hashed/Encrypted Security Checked Security Checked Security Checked	6/8/2023 8:54:55 AM 6/8/2023 8:58:41 AM 6/8/2023 8:59:22 AM 6/8/2023 8:59:22 AM	
Payment Events	Status	Timestamps	
Electronic Record and Signature Disclosure			

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, CV Sciences - Part 11 (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact CV Sciences - Part 11:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: vandana.kothari@cvsciences.com

To advise CV Sciences - Part 11 of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at vandana.kothari@cvsciences.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from CV Sciences - Part 11

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to vandana.kothari@cvsciences.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with CV Sciences - Part 11

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to vandana.kothari@cvsciences.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process.

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <u>https://support.docusign.com/guides/signer-guide-signing-system-requirements</u>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify CV Sciences Part 11 as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by CV Sciences Part 11 during the course of your relationship with CV Sciences Part 11.